C反应蛋白不是心血管病的干预靶点
运动、饮食结构的合理调节、降低体重、戒烟均可以达到一定程度的降低CRP水平的作用。
5 CRP不是心血管病干预的新靶点
综上所述，现有众多的证据显示血清中CRP水平长期增高是心血管病重要的危险因素之一。按照JUPITER研究的结论， hsCRP可以作为是否使用他汀用于心血管病一级预防的重要参考依据，因此在50岁以上的男性和60岁以上的女性测定血清hsCRP水平是有意义的。尤其是对于处在中等危险水平（Framingham 10年风险水平为10％～20％）和存在代谢综合征患者hsCRP的临床参考价值较大。目前hsCRP已被用做许多心血管危险度积分的重要指标。然而由于目前并无证据显示CRP参与了动脉粥样硬化和心血管病的发病过程，而且迄今为止还没有一项临床试验证实hsCRP的降低不依赖于降低血脂而能减少心血管病的发生，此外 JUPITER研究的结论需要在包括亚洲人在内的其他人群中进一步得到验证。现有的指南或共识并没有将hsCRP列为心血管病一级或二级预防中需要干预的指标，因此可见，CRP尚且不是心血管病干预的新靶点。
参考文献
[1] Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol. 2009 Oct;20(5):393-401.
[2] Watson KE. The JUPITER trial: How will it change clinical practice? Rev Cardiovasc Med. 2009 Spring;10(2):91-96.
[3] Kones R. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-315.
[4] Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):521-524.
[5] Martínez VB, González-Juanatey JR. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination. Am J Cardiovasc Drugs. 2009;9 Suppl 1:3-7.
[6] Lavie CJ, Milani RV, Verma A, O＇Keefe JH. C-reactive protein and cardiovascular diseases--is it ready for primetime? Am J Med Sci. 2009 Dec;338(6):486-492.
[7] Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010 Feb;17(1):1-11.
[8] Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010 Jan;6(1):27-34.
[9] Bajpai A, Goyal A, Sperling L. Should we measure C-reactive protein on earth or just on JUPITER? Clin Cardiol. 2010 Apr;33(4):190-198.
[10] Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol. 2010 Mar;26 Suppl A:41A-44A.
[11] Joshi PH, Jacobson TA. Therapeutic options to further lower C-reactive protein for patients on statin treatment. Curr Atheroscler Rep. 2010 Jan;12(1):34-42.
